• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

p53 和 PTEN 肿瘤抑制基因在非小细胞肺癌患者中的共改变。

Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients.

机构信息

Department of Neurobiology University of Belgrade, Institute for Biological Research, Republic of Serbia.

出版信息

Transl Res. 2011 Jan;157(1):19-28. doi: 10.1016/j.trsl.2010.09.004. Epub 2010 Oct 12.

DOI:10.1016/j.trsl.2010.09.004
PMID:21146147
Abstract

The inactivation of p53 and PTEN tumor suppressor genes is a common genetic event in lung cancer. However, data on the effect of the joint inactivation of tumor-suppressor genes in non-small cell lung carcinoma (NSCLC) are lacking. The purpose of this study was to investigate the alterations in PTEN and p53 genes, as well as to evaluate their mutual role in NSCLC pathogenesis and their impact on survival rate. To that end, polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP), sequencing, methylation-specific PCR, and fragment analysis were used. The results obtained were correlated with clinicopathologic parameters, the level of genomic instability, and patient survival. Overall, 13% of specimens had aberrant p53 only, 13% had inactive PTEN only, and 50% of samples had both genes altered. Correlation analyses showed that the mutual inactivation of p53 and PTEN was a frequent event that was associated significantly with the increased level of genomic instability and lymph node invasion implying their synergistic effect in promoting metastatic phenotype of this kind of cancer. In addition, our results revealed a significant association of joint alterations of these genes with dramatically shortened survival indicating that aberrant p53 and PTEN could be used as an adverse prognostic factor for NSCLC patients' outcome. Our findings established the relevance of the combinatorial inactivation of p53 and PTEN in NSCLC progression and identified a subgroup of patients with a particularly aggressive disease.

摘要

抑癌基因 p53 和 PTEN 的失活是肺癌中的常见遗传事件。然而,关于非小细胞肺癌(NSCLC)中肿瘤抑制基因共同失活的影响的数据尚缺乏。本研究的目的是研究 PTEN 和 p53 基因的改变,并评估它们在 NSCLC 发病机制中的相互作用及其对生存率的影响。为此,我们采用了聚合酶链反应单链构象多态性(PCR-SSCP)、测序、甲基化特异性 PCR 和片段分析。将获得的结果与临床病理参数、基因组不稳定性水平和患者生存率相关联。总体而言,13%的标本仅有异常的 p53,13%的标本仅有失活的 PTEN,而 50%的标本有这两个基因的改变。相关性分析表明,p53 和 PTEN 的相互失活是一种常见事件,与基因组不稳定性水平的增加和淋巴结侵犯显著相关,提示它们在促进这种癌症的转移表型方面具有协同作用。此外,我们的结果显示,这些基因的共同改变与生存率的显著缩短显著相关,表明异常的 p53 和 PTEN 可作为 NSCLC 患者预后的不良预后因素。我们的研究结果确立了 p53 和 PTEN 联合失活在 NSCLC 进展中的相关性,并确定了具有特别侵袭性疾病的患者亚组。

相似文献

1
Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients.p53 和 PTEN 肿瘤抑制基因在非小细胞肺癌患者中的共改变。
Transl Res. 2011 Jan;157(1):19-28. doi: 10.1016/j.trsl.2010.09.004. Epub 2010 Oct 12.
2
Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.非小细胞肺癌、神经胶质瘤和乳腺癌样本中p53、PTEN和p16的单个及多个改变的比较分析。
Biomed Pharmacother. 2014 Jun;68(5):521-6. doi: 10.1016/j.biopha.2014.03.014. Epub 2014 Mar 28.
3
Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients.p16 和 PTEN 肿瘤抑制基因的同时改变可被视为 NSCLC 患者特定亚组的潜在分子标志物。
Cancer Biomark. 2011;10(6):277-86. doi: 10.3233/CBM-2012-0257.
4
Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.p53基因第7和8外显子突变作为非小细胞肺癌患者预后不良的因素
Oncogene. 1998 May 14;16(19):2469-77. doi: 10.1038/sj.onc.1201776.
5
p53 gene mutations in non-small cell lung cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis.通过聚合酶链反应单链构象多态性分析检测非小细胞肺癌中的p53基因突变。
Chin Med Sci J. 1999 Sep;14(3):134-7.
6
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.p53和K-ras基因的突变作为非小细胞肺癌的预后因素
Int J Oncol. 1998 Mar;12(3):553-63. doi: 10.3892/ijo.12.3.553.
7
Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.新辅助化疗后非小细胞肺癌患者的长期生存与特定分子改变相关。
Exp Mol Pathol. 2015 Feb;98(1):27-32. doi: 10.1016/j.yexmp.2014.11.010. Epub 2014 Nov 20.
8
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.血浆DNA、微卫星改变和p53肿瘤突变与根治性切除的非小细胞肺癌患者的无病生存期相关:佩鲁贾胸科肿瘤多学科团队的一项研究
J Thorac Oncol. 2008 Apr;3(4):365-73. doi: 10.1097/JTO.0b013e318168c7d0.
9
Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.在非小细胞肺癌患者中,拓扑异构酶IIα基因的表达受p53肿瘤抑制基因调控。
Cancer. 2002 Apr 15;94(8):2239-47. doi: 10.1002/cncr.10450.
10
Association between p53 mutation and clinicopathological features of non-small cell lung cancer.p53突变与非小细胞肺癌临床病理特征之间的关联。
Jpn J Clin Oncol. 1997 Aug;27(4):211-5. doi: 10.1093/jjco/27.4.211.

引用本文的文献

1
Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of , , and mutations.非小细胞肺癌中肿瘤微环境和免疫治疗耐药性的遗传驱动因素:、和突变的作用。
J Immunother Cancer. 2025 Aug 5;13(8):e012288. doi: 10.1136/jitc-2025-012288.
2
Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro.姜烯酮载液质纳米粒抑制非小细胞肺癌的体外增殖和迁移。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan;397(1):343-356. doi: 10.1007/s00210-023-02603-5. Epub 2023 Jul 13.
3
Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer.
基于泛素特异性蛋白酶、信号通路和E3连接酶的非小细胞肺癌靶向治疗
Front Oncol. 2023 Mar 9;13:1120828. doi: 10.3389/fonc.2023.1120828. eCollection 2023.
4
Mutation and up-regulation of TP53 in ovine pulmonary adenocarcinoma lung cells as a model of human lung cancer.作为人类肺癌模型的绵羊肺腺癌细胞中TP53的突变与上调
Vet Res Forum. 2022 Sep;13(3):349-356. doi: 10.30466/vrf.2021.128764.2976. Epub 2022 Sep 15.
5
Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.CXCR4 和 FAK 抑制剂对相互失活的 p53 和 PTEN 抑癌基因的非小细胞肺癌的抗侵袭作用。
Invest New Drugs. 2017 Dec;35(6):718-732. doi: 10.1007/s10637-017-0494-4. Epub 2017 Jul 22.
6
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.单核苷酸多态性作为非小细胞肺癌的易感性、预后和治疗标志物。
Lung Cancer (Auckl). 2011 Dec 29;3:1-14. doi: 10.2147/LCTT.S13256. eCollection 2012.
7
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.靶向 CXCR4 和 FAK 逆转多柔比星耐药并抑制非小细胞肺癌侵袭。
Cell Oncol (Dordr). 2017 Feb;40(1):47-62. doi: 10.1007/s13402-016-0304-6. Epub 2016 Nov 7.
8
Anti-angiogenic efficacy of 5'-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs.5'-三磷酸小干扰RNA联合VEGF沉默和RIG-I激活在非小细胞肺癌中的抗血管生成疗效
Oncotarget. 2015 Oct 6;6(30):29664-74. doi: 10.18632/oncotarget.4869.
9
Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.CCND1过表达与非小细胞肺癌特定亚型中KRAS和PTEN改变的关联及其对患者预后的影响。
Tumour Biol. 2015 Nov;36(11):8773-80. doi: 10.1007/s13277-015-3620-y. Epub 2015 Jun 9.
10
Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus.双靶向PTEN和p53的微小RNA的特征鉴定确定微小RNA-638/Dnm2为双打击致癌位点。
Cell Rep. 2014 Aug 7;8(3):714-22. doi: 10.1016/j.celrep.2014.06.064. Epub 2014 Jul 31.